drugset / Trial / NCT01284582
Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase 1 Study :Safety, Immunogenicity and Dose response of ATH03, a new vaccine against the cholesterol ester transfer protein (CETP), in healthy male subjects with high density lipoprotein cholesterol (HDLc) blood concentrations equal or below 80 mg/dl.
Timeline
- Start
- 2011-05
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATH03 | Vaccine | 10 ug | — |
| Subject | ATH03 | Vaccine | 30 ug | — |
| Subject | ATH03 | Vaccine | 100 ug | — |
Indications
No indication recorded.